Dr. Jonasch on Alternative Sunitinib Scheduling for mRCC

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).

This study was testing the hypothesis that changing the schedule of sunitinib would allow patients to have lower toxicity rates and improve time on treatment and efficacy, states Jonasch. The primary endpoint was decreased grade 3 toxicity, which was not met during this study.

The patients who stayed on the study for a long period of time experienced a progression-free survival of 19 months and a response rate of 55%.